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Letters to the Editor to count as a near-universal belief. If so, I think his worry is misplaced. "The vagueness of near-universal does not imply that claims about a near-universal belief cannot be true." The claim that there is a lot of sugar in the pudding is vague but can be true or false.) The important issue, of course, is whether reductionism is a view that is dominant in psychiatry-whether it motivates theory, affects treatment, and drives research. I hardly think that anyone could deny this. If the minority of psychiatrists who are anti-reductionists is, in fact, growing, I can only welcome the news that there is less work to do than I had thought.
Ian Gold, PhD Montreal, Quebec
The Absence of a Placebo Group Is a Serious Limitation of the STAR*D Trial
Dear Editor: Given the complexity of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial, we appreciated Sinyor et al's 1 lucid review. The absence of a placebo group, however, is a serious limitation of STAR*D that deserved greater emphasis, particularly in light of recent meta-analyses of randomized controlled trials (RCTs) of antidepressants (ADs).
2-3 Although we agree that "inclusion of a placebo arm would have meant a departure from the principle of pragmatism," 1, p 134 the existing evidence did not justify such a purely pragmatic trial. Comparing active treatments without a placebo group is appropriate when at least one of the treatments has established benefits, but according to the metaanalyses cited, ADs have little or no benefit compared with placebo for mild to moderate depression. This has particular implications for STAR*D, which included many mildly depressed patients.
We recognize that the findings of the meta-analyses are controversial. Even if these studies are set aside, however, it remains that the superiority of ADs over placebo has not been established in depressed patients who are treated not in standard RCTs but in the real-world settings of STAR*D. The absence of a placebo group may improve STAR*D's generalizability to clinical practice, but the considerable cost is that the trial provides little information about the effectiveness of the treatments in this context. Indeed, given the striking result that no differences were found between medications with completely different mechanisms of action, it is likely that nonspecific factors-such as the placebo effect and the experience of being in treatment-were much more important than the specific treatments themselves. Further, as depression is typically an episodic illness that remits on its own within a year, 4 and STAR*D lasted about a year for patients who progressed to the end of the fourth treatment level, it is difficult to interpret the cumulative 67% remission rate in patients who remained in the study. The meaning of this figure becomes even less clear when one considers that many patients dropped out of the study or relapsed during the 12-month naturalistic follow-up.
The authors conclude that the results of STAR*D "have shed important light on the effectiveness of current treatment strategies for patients with depression." 1, p 134 However, we would argue that because of the absence of a placebo group, STAR*D obscures more than it illuminates. In fact, the very decision not to include a placebo group implies that the benefits of ADs are better established than current evidence suggests.
Reply..
Re: The Absence of a Placebo Group Is a Serious Limitation of the STAR*D Trial
Dear Editor:
We would like to thank Dr Gorman and Dr Abi-Jaoude for their letter. It provides us with an important opportunity to clarify the distinction between pragmatic and explanatory trials. Explanatory trials are designed to test whether a specific treatment has added benefit over placebo in a homogenous patient population. In contrast, pragmatic trials are designed to test how a heterogeneous, more typical patient population responds to interventions under a closer approximation of the conditions found in clinical practice, that is, in the real world.
In any trial design there are tradeoffs and STAR*D's pragmatic design, omitting a placebo arm, did not allow authors to ask the question of whether it was a failed trial; that is, were all treatments equally effective or equally ineffective. However, this does not interfere with our ability to interpret the results. STAR*D provides clinically relevant benchmarks for treatment response at each level in addition to a host of important secondary outcomes. Dr Gorman and Dr Abi-Jaoude state that The Canadian Journal of Psychiatry, Vol 56, No 2, February 2011 W Letters to the Editor nonspecific factors were more important than the specific treatment factors because there were no differences at each level. However, nonspecific factors are present in both explanatory and pragmatic trials, and there is no evidence that they were more important than usual in STAR*D. Therefore, while we felt it necessary to acknowledge in our review that STAR*D could not answer the sorts of questions that explanatory trials can answer, we are not of the opinion that this means the study's value as a pragmatic trial is in any way diminished.
Dr Gorman and Dr Abi-Jaoude suggest that it is difficult to interpret the 67% cumulative remission rate in STAR*D because of the length of the trial. However, one of the hallmarks of a well-designed pragmatic study is a longer trial length, 1 making STAR*D's length a strength. More importantly, the study quoted by Dr Gorman and Dr Abi-Jaoude followed a group of patients whose untreated depression had a median time to remission of 13 weeks. By comparison, patients in STAR*D entered the trial with a median current episode length of 7.8 months 2 indicating a higher degree of illness chronicity that would, in general, be unlikely to remit spontaneously on a short time scale.
Pragmatic trials are valuable tools for determining the real-world impact of the treatments we offer. As such, they are often sought after by health system funders and government agencies. Explanatory trials also have their value; nonetheless, both of these types of trials must be judged on their quality rather than on the presence or absence of a placebo arm. Placebo-controlled trials help answer certain questions but are not the sole way to obtain valuable and meaningful data on treatment comparisons. Trial," 1 Dr Neil A Rector et al discussed the limited efficacy of cognitive-behavioural therapy (CBT) for obsessive-compulsive disorder (OCD) with a comorbid diagnosis of major depression. We share with the authors the experience of having evaluated the effectiveness of first-line treatments in a nonpure OCD population. Interestingly, we found similar results.
Most of the clinical trials investigating treatments for OCD exclude patients with secondary psychiatric diagnoses. Although the methodology ensures a homogeneous sample, the results are limited regarding their generalization to a wider population, especially when the disorder occurs with a high level of psychiatric comorbidity-about 90% of OCD patients have a second psychiatric diagnosis during their lifetime. 2 We run a treatment service specialized in OCD as a primary diagnosis in which selective serotonin reuptake inhibitors (SSRIs) and group CBT are offered as first-line treatments. Our inclusion criteria are much broader than the ones from clinical trials with regulatory purposes but our treatment protocol is a structured one with sequential evaluations performed by blinded raters. Our sample has a comorbidity profile of up to 81% of patients having an additional psychiatric comorbidity. In a recent analysis of this sample, we found that response rates are much lower than previously reported and that major depression (among other psychiatric disorders) was associated with poor treatment response.
These findings suggest that OCD is much harder to treat than previous trials have estimated. Additional interventions may be needed in combination with SSRIs and CBT for patients with several psychiatric diagnoses. Future studies investigating longer treatment protocols, sequential treatment strategies, and contingencies analysis (functional analysis) are possible alternatives to improve the outcome of more complex samples.
